Supporters

Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. are the US-based indirect subsidiaries of the global healthcare company Otsuka Pharmaceutical Co. Ltd with the corporate philosophy: “Otsuka–people creating new products for better health worldwide.” Otsuka’s US companies share a deep commitment to the development and commercialization of innovative products in the spaces of neuroscience, nephrology, and immunology. At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere.

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve.

STARS is a nonprofit organization dedicated to improving the lives of individuals who stutter by advancing neuroscience-based research and comprehensive treatment methods. STARS is focused on uncovering the neurological causes of stuttering, with the goal of increasing global awareness and understanding of the condition. Through groundbreaking research and innovation, we aim to reduce the stigma and discrimination faced by those who stutter. STARS is committed to educating the greater healthcare community to facilitate access for individuals who stutter to receive comprehensive therapies. We are committed to developing new treatments today while working towards discovering cures for tomorrow. Address: 3151 Airway Avenue Building A3. Costa Mesa, CA 92626 USA
Contact Person: Gerald A Maguire MD
Email: GMaguireMD@stutteringresearch.org

Newron Pharmaceuticals SpA is a biopharmaceutical company dedicated to developing innovative therapies for patients with diseases of the central and peripheral nervous system. Founded in 1999 and headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA, the company focuses on addressing significant unmet medical needs in difficult-to-treat conditions such as Treatment-resistant schizophrenia, Parkinson’s disease, and other areas where therapeutic innovation has been limited for decades. Building on >25 years of proprietary scientific research and clinical development, Newron’s multidisciplinary team of approximately 30 scientists, researchers, and clinicians works to advance novel drug candidates from discovery through clinical development toward commercialization. Address: via Antonio Meucci 3 20091 Bresso (MI) Italy

Viatris is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address global healthcare needs. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale—supplying medicines to approximately 1 billion patients around the world.

Visit the Wisepress stand to view our extensive range of books and journals relevant to this conference. We work with multiple publishers to ensure that our books are the best available in your specialism.
Wisepress.com is Europe’s leading conference bookseller, attending 150 conferences a year with titles also available on our online bookshop at www.wisepress.com. Want to make a bulk order? Contact us at bookshop@wisepress.com

NCNP-CINP Co-Sponsored Symposium: Advancing Addiction Research from Japan
The National Center of Neurology and Psychiatry (NCNP), Japan’s leading institution for mental health and neuroscience, plays a central role in advancing addiction research through an integrated approach spanning basic neuroscience, clinical research, and public health.
Addiction remains a major global challenge, influenced by complex interactions among genetic, environmental, and social factors. In Japan, unique characteristics of addiction—such as genetic backgrounds affecting alcohol metabolism and sociocultural patterns of substance use—provide valuable opportunities for scientific discovery.
NCNP is promoting a large-scale addiction research initiative supported by national funding, aiming to:

• Elucidate neurobiological mechanisms of addiction
• Identify genetic and environmental risk factors
• Develop biomarkers for diagnosis and treatment
• Promote translational research from bench to bedside
• Development and dissemination of a psychosocial approach
• Contribute to international collaborative research

This symposium highlights cutting-edge research from NCNP, including organoid-based disease modeling, genetic studies, and neuropharmacological approaches, and aims to strengthen global collaboration in addiction research.